Tag:
Abbott Laboratories
Latest Headlines
Latest Headlines
A strike against sales-rep OT as Lilly, Abbott win appeal
A U.S. appeals court has denied overtime for Eli Lilly and Abbott Laboratories sales reps.
12-year-old consent decree lifted from Abbott
Abbot Laboratories has shed the smell of a consent decree more than a decade after its imposition and just before it splits itself up for the public markets.
Abbott to pay $1.6B to wrap up Depakote marketing probe
It's the second-largest off-label marketing settlement ever, topped only by Pfizer's $2.3 billion deal.
Abbott hits the sweet spot, pays $110M cash for PhIIb drug
The cash deal delivers AP214, in development to prevent acute kidney injury associated with major cardiac surgery.
Men flock to testosterone meds from Abbott, Lilly
Are testosterone drugs another hormone-replacement ordeal in the making? Some doctors think so, Bloomberg reports.
Abbott tries to throw up roadblock to Humira biosim
The Chicago-based company petitioned the FDA to stop biosimilar versions of Humira, its lead drug, on trade-secret grounds.
Abbott tries to throw up roadblock to Humira biosim
While Pfizer was reporting a 71% drop in U.S. Lipitor sales and plotting its next spin-off move, Abbott Laboratories was working to shore up its own breakup plans by protecting its pharma unit's lead drug.
Amgen founding CEO George Rathmann dies at 84
In the years after he took the helm of the company, Rathmann helped steer the development of Epogen and Neupogen. Only now does Amgen face rivals to its anemia franchise.
FDA hits brakes on Novartis' hep C program after death
U.S. regulators have put a hold on Novartis' clinical trial for experimental hepatitis C drug alisporivir after cases of pancreatitis were reported in the trial and one patient in the study died.
Abbott touts positive Parkinson's Phase III as pharma split looms
Banking on double-digit earnings growth and a string of pipeline deals and developments, Abbott Laboratories execs said they are "on track" to go ahead and spin off the pharma side of the business later this year.
